NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The DSUR provides an a...
Revealing Statistics Question If Psychedelics Truly Impact Religious Beliefs
Journalist Don Lattin writes that a new study examining the impact of psychedelic use on religious experiences supports his view that much of psychedelic research and journalism takes place in an echo chamber of self-...
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about spectacle and more about structure. The i...
Delix Therapeutics Reports Strong Phase Ib Results
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
This qualitative study (n=40) of healthy males following a double-blind placebo-controlled trial of LSD microdosing (10µg every third day for 6 weeks) found participants reported effects across emotions and mood, soci...
LSD microdosing in major depressive disorder: results from an open-label trial
This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events ...
Cognitive and Subjective Effects of Psilocybin Microdosing: Results from Two Double-Blind Placebo-Controlled Longitudinal Trials
These two randomised, double-blind, placebo-controlled trials (n=141) conducted in semi-naturalistic settings found that microdosing psilocybin truffles did not significantly affect cognitive control, memory, social c...
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers
This randomised, placebo-controlled study (n=48) examining LSD microdosing (15 μg) for analgesia in healthy participants found no significant pain-relieving effects on pain tolerance or subjective pain perception usin...
Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice
This pre-clinical mouse study tested chronic administration of serotonin, d-fenfluramine, or subhallucinogenic doses of LSD on cardiovascular health. Serotonin and d-fenfluramine caused ventricular thickening and valv...
MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans
August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization (CRO) for MJP...
Health-related behavioral changes following the use of psychedelics in naturalistic settings
This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (...
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant advers...
Women’s Health and Psychedelics – New Insights
Using validated behavior models and known standards, studies are finding significant differences between male and female rodents given psychedelic drugs.
First Proof that Psilacetin is a Prodrug of Psilocin
Nichols and Frescas’ 1999 hypothesis becomes a validated scientific theory.
Magic Mushroom Formulations Update
Magic mushroom science marches on as understudied psilocybin derivatives start taking center stage.